ESBD_521004_1780004199247_Exhibit A-8 - Top 50 Drugs Report.xlsx

This is a Top 50 Drugs Report for Central Health, a healthcare entity managing pharmaceutical utilization and costs. The document presents claims data covering the period from February 2025 through June 2025 (202503-202602), detailing the most expensive and frequently utilized drugs in the organization's formulary. The report identifies 50 high-impact medications across multiple therapeutic categories, including specialty pharmaceuticals for conditions such as hemophilia, rheumatological disorders, oncology, infectious disease, endocrinology, and psychiatry. Each drug entry includes the National Drug Code (NDC), drug name, dosage form, member count, prescription count, and total plan-paid amounts. The data reveals significant pharmaceutical expenditures, with top drugs such as HEMLIBRA ($685,946), STELARA ($444,140.54), and VERZENIO ($426,387.02) representing the highest costs during the reporting period.

The report categorizes drugs by numeric tier levels (ranging from 1 to 3), specialty universal flags, and prior authorization or step therapy requirements. Most specialty medications in the top tier require prior authorization (PA) or smart logic PA protocols to manage utilization and ensure appropriate prescribing. The document includes comprehensive NDC information cross-referenced with Aetna DL numbers and GPI codes, indicating integration with pharmacy benefit management systems. The second section of the file contains an extended formulary reference table listing additional product names and their corresponding NDC codes, particularly focusing on psychiatric, ophthalmic, and neurological medications. This data serves as a management and benchmarking tool for evaluating pharmaceutical spend, identifying utilization patterns, and informing formulary and prior authorization strategy decisions.